TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
0 hedge funds and large institutions have $0 invested in TCR2 Therapeutics Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 59 closing their positions.
100% less funds holding
Funds holding: 59 → 0 (-59)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $31.4M → $0 (-$31.4M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 59
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$6.08M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$5.1M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$5.06M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.2M |
| 5 |
NM
Newtyn Management
New York
|
-$1.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Group One Trading
Chicago,
Illinois
| – | -$1.2K | -800 | Closed |
|
52
US Bancorp
Minneapolis,
Minnesota
| – | -$1.05K | -700 | Closed |
|
|
FDCDDQ
53
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$750 | -500 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$351 | -234 | Closed |
|
55
BNP Paribas Financial Markets
Paris,
France
| – | -$210 | -140 | Closed |
|
|
BHWM
56
Beaird Harris Wealth Management
Dallas,
Texas
| – | -$92 | -61 | Closed |
|
|
SIC
57
Salem Investment Counselors
Winston Salem,
North Carolina
| – | -$53 | -35 | Closed |
|
|
IRC
58
Investors Research Corp
Atlanta,
Georgia
| – | -$23 | -15 | Closed |
|
TCRR Hedge Fund Activity: Q2 2023 in Review
0 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q2 2023, worth a combined $0 — down 100% from $31.4M a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of TCRR and 0 opened new positions — a net loss of 59 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was MPM Asset Management, exiting entirely with an estimated $6.08M sold.
- 0 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q2 2023, down from 59 in Q1 2023.
- Funds reported $0 of TCR2 Therapeutics Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q2 2023 and 59 closed out, a net change of -59 holders.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q2 2023 was MPM Asset Management, an estimated $6.08M sold.
Based on aggregated 13F filings for Q2 2023.